59 Results
Sort By:
Published on June 22, 2020
Acute myeloid leukemia (AML) is a malignant clonal disease originating from myeloid hematopoietic stem/progenitor cells. It is a quickly progressing disease in which too many abnormal white blood cells are found in the bone marrow. AML is the second most common form of leukemia in children after acute lymphoblastic leukemia…
Published on April 6, 2020
T cells engineered to brandish three prongs—chimeric antigen receptors (CARs)—can kill cancer cells more efficaciously than single-pronged or even double-pronged CAR T cells, let alone ordinary, unmodified T cells. New research demonstrates that triple-pronged CAR T cells may be better at overcoming antigen escape relapse, which can occur when cancer…
Published on December 31, 2019
Alex Trebek appeared well en route to surviving pancreatic cancer this past summer when his doctors followed up his initial successful chemotherapy with an undisclosed immunotherapy. That move backfired. “I was doing so well. And my numbers went down to the equivalent of a normal human being who does not…
Published on November 15, 2019
Researchers from Cellectis have published a proof-of-concept study detailing the activity of “smart” T-cells capable of sensing and reacting to tumors with micro secretions of therapeutic proteins that improve their ability to fight cancerous cells, potentially paving the way for a next generation of tightly-controlled, highly active—and potentially safer—CAR T-cell…
Published on August 29, 2019
The Leukemia & Lymphoma Society (LLS) said it has more than doubled its funding of research into childhood blood cancers, adding 20 new grants valued at more than $13.8 million to its 2019 portfolio. The new pediatric grants are part of the LLS Children’s Initiative: Cures and Care for Children,…
Published on June 28, 2019
Personalized diagnostics and therapeutics developer Adaptive Biotechnologies has raised at least $300 million in gross proceeds through an initial public offering (IPO)—the second-largest one for a biopharma company so far this year—then saw its share price double as investors flocked to the stock. Shares of Adaptive debuted for trading June…
Published on April 22, 2019
Gasdermine E (GSDME) is an important regulator of cell death which is suppressed in various types of cancers. Researchers at Sidney Kimmel Cancer center recently discovered that the pore-forming protein acts through multiple pathways, targeting both cellular and mitochondrial membranes to mediate cell lysis and mitochondrial apoptosis, respectively. Their study,…
Published on January 31, 2018
The FDA’s embrace of precision oncology, along with increases in the number and rate of survival, were highlighted today by the American Society of Clinical Oncology (ASCO) as examples of clinical progress in the fight against cancer. In “Clinical Care Advances 2018,” ASCO cited as its “Advance of the Year”…
Published on December 19, 2017
Spark Therapeutics' Luxturna (voretigene neparvovec-rzyl), a gene therapy for treating children and adults with the rare inherited blindness disorder biallelic RPE65 mutation-associated retinal dystrophy has been approved by the FDA. The one-time adeno associated viral vector (AAV)-delivered gene therapy is “a milestone that reinforces the potential of this breakthrough approach…
Published on November 21, 2017
Researchers at Cardiff University in Wales have used the CRISPR/Cas9 gene editing technology to engineer killer T cells that are up to a thousand times more sensitive to cancer cell antigens than T cells engineered using more conventional approaches, and which allowed far better targeting of T cells to cancer…
Published on October 3, 2017
Since Hyder F. Brewster, M.D., and Herbert E. Cannon, M.D., first reported the occurrence of acute lymphoblastic leukemia (ALL) in an 11-month-old with Down syndrome in 1930, numerous studies have confirmed that children with structural birth defects are at much higher risk of developing certain childhood cancers—including increased leukemia risk…
Published on August 31, 2017
Novartis’ Kymriah (tisagenlecleucel) will be the first chimeric antigen receptor T-cell (CAR-T) cancer immunotherapy to reach the U.S. market following FDA approval yesterday. Kymriah, previously known as CTL019, is indicated for the treatment of second or later relapsed or refractory (r/r) patients up to age 25 with B-cell acute lymphoblastic…
Published on June 21, 2017
Adaptive Biotechnologies said today it will partner with Johnson & Johnson’s Janssen Biotech to develop its next-generation sequencing (NGS)-based clonoSEQ Assay as a companion diagnostic in ongoing and future clinical trials assessing Darzalex (daratumumab) in patients with multiple myeloma (MM). The value of the collaboration was not disclosed. The companies…
Published on December 6, 2016
A team of investigators at the University of Basel's Biozentrum that has been researching the expression of ribosomal proteins in a wide range of human tissues, including tumors recently discovered a cancer type specific signature. The findings from this new study, published recently in Genome Biology through an article entitled…